Charcot-Marie-Tooth disease type 4B2 (Q104665): Difference between revisions

From determinar.ia.br - Determine suas informações
‎Created a new Item
 
‎Changed label, description and/or aliases in pt-br, en
description / pt-brdescription / pt-br
 
A doença de Charcot-Marie-Tooth tipo 4B2 (CMT4B2) é uma polineuropatia periférica sensitivomotora da CMT desmielinizante grave de início precoce com fraqueza muscular de início na infância, perda sensitiva, velocidades de condução nervosa reduzidas, desdobramentos de mielina característicos e um curso grave da doença. Além da neuropatia grave, os pacientes de algumas famílias com CMT4B2 também desenvolvem glaucoma de início precoce.
description / endescription / en
 
Charcot-Marie-Tooth disease, type 4B2 (CMT4B2) is a severe early-onset demyelinating CMT peripheral sensorimotor polyneuropathy with childhood-onset of muscle weakness, sensory loss, reduced nerve conduction velocities, characteristic myelin outfoldings and a severe disease course. In addition to the severe neuropathy, patients from some CMT4B2 families also develop early-onset glaucoma.

Revision as of 10:31, 17 August 2026

Charcot-Marie-Tooth disease, type 4B2 (CMT4B2) is a severe early-onset demyelinating CMT peripheral sensorimotor polyneuropathy with childhood-onset of muscle weakness, sensory loss, reduced nerve conduction velocities, characteristic myelin outfoldings and a severe disease course. In addition to the severe neuropathy, patients from some CMT4B2 families also develop early-onset glaucoma.
Language Label Description Also known as
default for all languages
ID_393759720
    English
    Charcot-Marie-Tooth disease type 4B2
    Charcot-Marie-Tooth disease, type 4B2 (CMT4B2) is a severe early-onset demyelinating CMT peripheral sensorimotor polyneuropathy with childhood-onset of muscle weakness, sensory loss, reduced nerve conduction velocities, characteristic myelin outfoldings and a severe disease course. In addition to the severe neuropathy, patients from some CMT4B2 families also develop early-onset glaucoma.

      Statements